Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04765098|
Recruitment Status : Recruiting
First Posted : February 21, 2021
Last Update Posted : April 6, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma Multiforme||Drug: Tamoxifen Drug: Etoposide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Controlled Trial of Tamoxifen Versus Etoposide for Patients With First Recurrence of Glioblastoma Multiforme|
|Actual Study Start Date :||January 28, 2022|
|Estimated Primary Completion Date :||August 2026|
|Estimated Study Completion Date :||December 2026|
|Active Comparator: Etoposide||
etoposide 50mg/m2 daily
Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
- 3 month progression-free survival [ Time Frame: 3 months ]Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.
- One-year progression-free survival [ Time Frame: 12 months ]Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.
- Overall survival [ Time Frame: Median, 6-month, 1-year, and 2-year OS rates will be measured ]Time between randomization and death due to any cause. Patients without an event will be censored the last time they were known to be alive.
- Health-related quality-of-life status [ Time Frame: Throughout study completion, up to 5 years. ]Health-related quality-of-life will be assessed using the EORTC QLQ-BN20 brain tumor module questionnaire. This is a self-report questionnaire consisting of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit in brain tumor patients
- Adverse events [ Time Frame: Throughout the whole duration of the trial, up to 5 years ]This includes fatigue, hematologic toxicities (neutropenia, thrombocytopenia, leukopenia, anemia), liver toxicities, hypertension, diarrhea, seizures and thrombosis and will all be recorded.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologically proven GBM with progression after previous first line chemoradiotherapy with temozolomide.
- Progression documented by MRI with at least one bi-dimensionally measurable target lesion with one diameter of at least 10 mm, visible on two or more axial slices 5 mm apart.
- Not received radiotherapy within the three months before the diagnosis of progression.
- Stable or decreasing dose of corticosteroids prior to randomization: corticosteroids (dexamethasone) should be given at the lowest dose needed to control symptoms arising from increased intracerebral edema.
- ECOG performance 0-2 (Appendix 2).
- Age from 18-65 years.
- Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior to the first dose of study treatment. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.
Patients of childbearing / reproductive potential should use adequate birth control methods, as defined by the investigator, during the study treatment period and for a period of 60 days after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
Laboratory evaluation obtained within 7 days prior to randomization, with adequate function as defined below:
- ANC ≥ 1.5 x 109/L
- Platelets ≥ 100 x 109/L
- Serum creatinine ≤ 1.5 times ULN
- Total serum bilirubin ≤ 1.5 times ULN
- ALT < 3 times ULN
- AST < 3 times ULN
- Alkaline phosphatase < 3 times ULN
- Patient must understand and sign an informed consent prior to study registration.
- History of another malignancy or a concurrent malignancy (exceptions include patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
- Uncontrolled hypertension (systolic blood pressure >150 mm Hg or diastolic blood pressure >100 mm Hg).
- Any arterial or venous thrombosis up to 6 months before registration.
- Evidence of recent hemorrhage on brain MRI.
- Substantial cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04765098
|Contact: Jacob Easaw, MD, PhD, FRCPCemail@example.com|
|Cross Cancer Institute||Recruiting|
|Edmonton, Alberta, Canada|
|Responsible Party:||AHS Cancer Control Alberta|
|Other Study ID Numbers:||
|First Posted:||February 21, 2021 Key Record Dates|
|Last Update Posted:||April 6, 2022|
|Last Verified:||March 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents